Snowball logo
logo
MYMD

MyMD Pharmaceuticals Inc

MYMD • NASDAQ Не торгуется
-- $0,00 $  (0%)
Оценка
EPS
-9,27
Рост
Чистый доход, YoY
-129,52%
FCF, YoY
31,92%
Другое
Размер лота
1 шт.
О компании
Тикер
MYMD
ISIN
US62856X1028
Страна
США
Сектор (GICS)
Здравоохранение
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Часто задаваемые вопросы

В каком секторе работает MyMD Pharmaceuticals Inc (MYMD)?

MyMD Pharmaceuticals Inc относится к сектору Здравоохранение.

Выплачивает ли MyMD Pharmaceuticals Inc (MYMD) дивиденды?

Нет, MyMD Pharmaceuticals Inc не выплачивает дивиденды.